Brady Stewart Purchases 30,000 Shares of Evolus (NASDAQ:EOLS) Stock

Key Points

• Brady Stewart, a director at Evolus, Inc., purchased 30,000 shares of stock for $204,600, increasing his position by 51.17% to a total of 88,629 shares.
• Evolus stock currently trades at $6.69, with a 52-week range of $5.71 to $17.82 and a market capitalization of approximately $432.71 million.
• Wall Street analysts have mixed opinions on Evolus, with a consensus average rating of "Moderate Buy" and a target price of $21.25, though some firms have recently reduced their price objectives.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) Director Brady Stewart purchased 30,000 shares of the stock in a transaction dated Friday, August 15th. The shares were acquired at an average price of $6.82 per share, with a total value of $204,600.00. Following the transaction, the director owned 88,629 shares in the company, valued at $604,449.78. This trade represents a 51.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Evolus Trading Up 3.4%

Shares of NASDAQ:EOLS traded up $0.25 during trading on Friday, hitting $7.68. 1,342,543 shares of the company's stock were exchanged, compared to its average volume of 2,289,617. Evolus, Inc. has a 1-year low of $5.71 and a 1-year high of $17.82. The firm has a 50-day moving average price of $8.62 and a two-hundred day moving average price of $10.62. The company has a current ratio of 2.27, a quick ratio of 1.86 and a debt-to-equity ratio of 22.00. The firm has a market cap of $496.74 million, a P/E ratio of -7.84 and a beta of 1.12.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Tang Capital Management LLC grew its holdings in Evolus by 3.1% during the fourth quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock valued at $55,171,000 after purchasing an additional 150,000 shares during the period. Vanguard Group Inc. lifted its stake in Evolus by 2.0% in the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company's stock valued at $38,906,000 after buying an additional 62,664 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in Evolus by 10.8% in the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company's stock valued at $34,557,000 after buying an additional 305,300 shares in the last quarter. Caligan Partners LP lifted its stake in Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock valued at $29,724,000 after buying an additional 498,900 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. bought a new position in Evolus in the second quarter valued at approximately $22,431,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. HC Wainwright lowered their price target on shares of Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. BTIG Research lowered their price target on shares of Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Needham & Company LLC reiterated a "hold" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, August 6th. Finally, Wall Street Zen cut shares of Evolus from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, Evolus currently has a consensus rating of "Moderate Buy" and an average target price of $21.25.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.